These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7373336)

  • 1. Oxpentifylline in Parkinson's disease.
    Godwin-Austen RB; Twomey JA; Hanks G; Higgins J
    J Neurol Neurosurg Psychiatry; 1980 Apr; 43(4):360-4. PubMed ID: 7373336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxpentifylline in dementia: a controlled study.
    Ghose K
    Arch Gerontol Geriatr; 1987 Apr; 6(1):19-26. PubMed ID: 3592847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of oxpentifylline on blood viscosity and cerebral blood flow in man.
    Brown MM
    Br J Clin Pharmacol; 1989 Oct; 28(4):488-92. PubMed ID: 2590608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxpentifylline treatment of venous ulcers of the leg.
    Colgan MP; Dormandy JA; Jones PW; Schraibman IG; Shanik DG; Young RA
    BMJ; 1990 Apr; 300(6730):972-5. PubMed ID: 2256974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
    Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
    Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic treatment of intermittent claudication.
    Porter JM; Bauer GM
    Surgery; 1982 Dec; 92(6):966-71. PubMed ID: 7147192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of circulation disorders with pentoxifylline. A double-blind study with Trental].
    Tonak J; Knecht H; Groitl H
    Med Monatsschr; 1977 Oct; 31(10):467-72. PubMed ID: 337089
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of Parkinson's disease with proglumide, a CCK antagonist.
    Piolti R; Appollonio I; Cocco E; Ferrarese C; Frattola L; Rovati L; Panerai AE
    Neurology; 1991 May; 41(5):749-50. PubMed ID: 2027496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intermittent claudication treated with pentoxifylline. A controlled trial].
    Skovborg F; Bonde-Petersen F; Bloch I; Christensen E
    Ugeskr Laeger; 1983 Nov; 145(47):3649-52. PubMed ID: 6362159
    [No Abstract]   [Full Text] [Related]  

  • 12. Livedo vasculitis. Therapy with pentoxifylline.
    Sams WM
    Arch Dermatol; 1988 May; 124(5):684-7. PubMed ID: 3364993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxpentifylline treatment of venous leg ulcers.
    Bittiner SB
    BMJ; 1990 Jun; 300(6738):1528. PubMed ID: 2372615
    [No Abstract]   [Full Text] [Related]  

  • 14. Oxpentifylline treatment of venous leg ulcers.
    Gajraj H; Jopp-McKay A; Stacey MC
    BMJ; 1990 Jun; 300(6741):1725. PubMed ID: 2390561
    [No Abstract]   [Full Text] [Related]  

  • 15. Adjunctive therapy with bromocriptine in Parkinson's disease.
    Temlett JA; Ming A; Saling M; Fritz VU; Blumenfeld A; Bilchik TR; Becker AL; Fourie PB; Reef HE
    S Afr Med J; 1990 Dec; 78(11):680-5. PubMed ID: 2251616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
    Olanow CW; Alberts MJ
    Adv Neurol; 1987; 45():555-60. PubMed ID: 3548266
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparative evaluation of the effectiveness of buflomedil and pentoxifylline in patients with arterial occlusive disease.
    Trübestein G; Trübestein R; Duong QD
    Angiology; 1981 Oct; 32(10):705-10. PubMed ID: 7034591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
    Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
    Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of mortality in pergolide-treated patients with Parkinson's disease.
    Sayler ME; Street JS; Bosomworth JC; Potvin JH; Kotsanos JG
    Neuroepidemiology; 1996; 15(1):26-32. PubMed ID: 8719046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.
    Schachter M; Marsden CD; Parkes JD; Jenner P; Testa B
    J Neurol Neurosurg Psychiatry; 1980 Nov; 43(11):1016-21. PubMed ID: 6777463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.